摘要
目的探讨氮卓斯汀滴眼液和富马酸依美斯汀滴眼液治疗过敏性结膜炎的临床疗效。方法回顾性分析2014年1月～2015年12月我院门诊收治的过敏性结膜炎患者112例，随机分成富马酸依美斯汀组和氮卓斯汀组，其中氮卓斯汀组50例，富马酸依美斯汀组62例，分别使用氮卓斯汀滴眼液和富马酸依美斯汀滴眼液点眼，并于用药前、用药后第3天和第7天询问患者症状并用裂隙灯进行眼前节检查，并对各观察项目进行评分及统计学处理，比较治疗前后眼部症状、眼部体征和临床疗效。结果用药后3d和7d，两组患者组内眼部临床症状和体征均明显改善，但两组患者疗效比较差异无统计学意义（P〉0．05）。结论氮卓斯汀滴眼液与富马酸依美斯汀滴眼液治疗过敏性结膜炎均安全有效。
Objective To investigate the clinical efficacy of azelastine and emedastine in treatment of allergic conjunctivitis. Methods Retrospectively analysed the clinical data＇ of 112 cases admitted to hospital from Jun 2014 to Dec 2015 in patients with allergic conjunctivitis. All cases were randomly divided into azelastine group and emedastine group. There were 50 cases in azelastine group and 62 cases in emedastine group. Azelastine eye drops and emedastine eye drops were used respectively, and before treatment, 3 days and 7 days after treatment, the patients were asked about symptoms and their eye anterior segment were checked with slit lamp,： and each observation score was projected and statistical analysis was performed, eye symptoms and signs and clinical efficacy were compared before and after treatment. Results Treatment efficacy was significant in 3 days and 7 days after treatment between the two groups, and the differences between the two groups were not statistically significant （P〉0.05）. Conclusion Azelastine and emedastine of the applications are safe and effective.
出处
《中国现代医生》
2016年第14期100-102,共3页
China Modern Doctor
基金
广东省深圳市科技计划项目(JCYJ20130401114111455)
